CN Patent

CN110191704A — 可分散组合物

Assigned to Janssen R&D Ireland ULC · Expires 2019-08-30 · 7y expired

What this patent protects

本发明涉及包含利匹韦林或其药学上可接受的酸加成盐作为活性成分的可分散组合物。此类组合物可用于治疗HIV感染，并且其分散性特性使得其特别适用于小儿或老年群体。

USPTO Abstract

本发明涉及包含利匹韦林或其药学上可接受的酸加成盐作为活性成分的可分散组合物。此类组合物可用于治疗HIV感染，并且其分散性特性使得其特别适用于小儿或老年群体。

Drugs covered by this patent

rilpivirine-hydrochloride (RILPIVIRINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN110191704A
Jurisdiction: CN
Classification: —
Expires: 2019-08-30
Drug substance claim: No
Drug product claim: No
Assignee: Janssen R&D Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.